Schnell Biopharmaceuticals Inc (003060)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013615)
◆英語タイトル:Schnell Biopharmaceuticals Inc (003060) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013615
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:27
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Schnell Biopharmaceuticals Inc (Schnell), formerly Korea Schnell Pharma Co., Ltd. is a healthcare company that offers agents and antibiotics. The company provides pharmaceutical products including amino acid infusion agents and antibiotics. Its products portfolio includes antibiotics, infusions, containing amino acid, vitamin and hepatic protect infusions; gastrointestinal agents, comprising of digestives and antiulcerants. Schnell offers musculoskeletal system agents, consisting of anti-inflammatory drugs, muscle relaxants, respiratory system agents, including expectorants, antitussives and antihistamines. The company produces vitamins and nutrition agents. It provides the other drugs such as antiemetics and antineoplastic agents. The company operates through its factory located in Hwaseong-si, Korea. Schnell is headquartered in Seongnam, South Korea.

Schnell Biopharmaceuticals Inc (003060) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Schnell Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Schnell Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Schnell Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Schnell Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Schnell Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Schnell Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Binex Forms Joint Venture with Aprogen 11
Schnell BioPharma Enters Into Co-Development Agreement With Aprogen And Chunggei Pharm 12
Licensing Agreements 13
Schnell BioPharma Enters Into Licensing Agreement With Aquapick 13
Schnell BioPharma Enters Into Licensing Agreement With AVVA 14
Debt Offering 15
Aprogen Pharma Raises USD20.6 Million in Public Offering of 2% Bonds Due 2022 15
Schnell Biopharma to Raise USD10 Million in Public Offering of 2% Bonds Due 2019 16
Schnell Biopharma to Raise USD9.2 Million in Public Offering of 2% Bonds Due 2019 17
Schnell BioPharma Completes Issue Of Ninth Unsecured Bonds Due 2014 For US$8.8 Million 18
Schnell BioPharma Completes Issue Of Eighth Unsecured Bonds Due 2014 For US$14.5 Million 19
Acquisition 20
Huacheng Travel Agency Plans to Acquire Schnell Biopharma 20
Gbase to Acquire 22% Stake in Aprogen for USD16 Million 21
Binex Completes Acquisition of 22% Stake in Aprogen for USD14 million 22
Schnell Biopharma Sells 50% Stake In CHUNG GEI Pharma For US$6.5 Million 23
Schnell Biopharmaceuticals Inc – Key Competitors 24
Schnell Biopharmaceuticals Inc – Key Employees 25
Schnell Biopharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Schnell Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Schnell Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Schnell Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Schnell Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Schnell Biopharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Schnell Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Binex Forms Joint Venture with Aprogen 11
Schnell BioPharma Enters Into Co-Development Agreement With Aprogen And Chunggei Pharm 12
Schnell BioPharma Enters Into Licensing Agreement With Aquapick 13
Schnell BioPharma Enters Into Licensing Agreement With AVVA 14
Aprogen Pharma Raises USD20.6 Million in Public Offering of 2% Bonds Due 2022 15
Schnell Biopharma to Raise USD10 Million in Public Offering of 2% Bonds Due 2019 16
Schnell Biopharma to Raise USD9.2 Million in Public Offering of 2% Bonds Due 2019 17
Schnell BioPharma Completes Issue Of Ninth Unsecured Bonds Due 2014 For US$8.8 Million 18
Schnell BioPharma Completes Issue Of Eighth Unsecured Bonds Due 2014 For US$14.5 Million 19
Huacheng Travel Agency Plans to Acquire Schnell Biopharma 20
Gbase to Acquire 22% Stake in Aprogen for USD16 Million 21
Binex Completes Acquisition of 22% Stake in Aprogen for USD14 million 22
Schnell Biopharma Sells 50% Stake In CHUNG GEI Pharma For US$6.5 Million 23
Schnell Biopharmaceuticals Inc, Key Competitors 24
Schnell Biopharmaceuticals Inc, Key Employees 25
Schnell Biopharmaceuticals Inc, Other Locations 26
Schnell Biopharmaceuticals Inc, Subsidiaries 26

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Schnell Biopharmaceuticals Inc (003060)-製薬・医療分野:企業M&A・提携分析(Schnell Biopharmaceuticals Inc (003060) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆